Previsión
El precio objetivo medio de los analistas es de 8,66 € (+368,11 %). La mediana es de 8,66 € (+368,11 %).
| Comprar |
2 |
| Mantener |
3 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
XenoTherapeutics completes acquisition of ESSA Pharma
XenoTherapeutics has completed the acquisition of ESSA Pharma and acquired all outstanding common shares through its subsidiary Xeno Acquisition Corp. for about $0.1242 per share. The previously revised terms were supplemented by a contingent value right (CVR) that can enable additional payments of up to $0.14 per share and up to $6.7 million in total. The acquisition was approved by the Supreme Court of British Columbia; ESSA has applied to delist from Nasdaq and plans an $80 million liquidation distribution to shareholders. » Más en de.investing.com
ESSA Pharma shareholders approve takeover by XenoTherapeutics
Holders of ESSA Pharma securities voted by an overwhelming majority (99.83% and 99.85% including options/warrants) to approve the takeover by XenoTherapeutics under a plan of arrangement. The transaction remains subject to court approval by the Supreme Court of British Columbia; the hearing is scheduled for October 7, 2025, and closing is expected around October 9, 2025. ESSA announced amended deal terms: the expected cash payment was reduced from 1.91 USD to about 0.12 USD per share, and shareholders will also receive a non-transferable CVR with a possible payment of up to 0.14 USD; additionally, an $80 million distribution to shareholders is planned. Shareholders also provisionally approved a voluntary liquidation in case the takeover fails and voted to approve the transaction-related compensation for executives. » Más en de.investing.com
ESSA Pharma gets court approval for meeting date for takeover by XenoTherapeutics
The Supreme Court of British Columbia approved the rescheduling of ESSA Pharma’s extraordinary general meeting to Oct. 3, 2025 as an online webcast; stakeholders can object until Oct. 1, and court approval of the deal is set for Oct. 7. XenoTherapeutics is to acquire all issued common shares of ESSA, but the merger terms were revised: the expected cash payout was cut from about $1.91 to roughly $0.12 per share and a non‑transferable CVR worth up to $0.14 was added. ESSA plans an $80m distribution to shareholders (payment date Aug. 22) and the acquisition financing comes from XOMA Royalty Corporation. The micro‑cap stock is trading near its 52‑week low and is down 74% year to date. » Más en de.investing.com
ESSA Pharma: changed merger terms drastically cut payout forecast, stock falls 17%
ESSA Pharma adjusted the terms of the merger with XenoTherapeutics, reducing the expected per-share payout from about $1.91 to roughly $0.12. Additionally, contingent value rights of up to $0.14 per share are to be issued, with payouts tied to specific events. The company cites updated cash estimates and potential liabilities as reasons; XOMA Royalty remains structuring agent and intends to finance the transaction. The stock fell 17% in premarket trading. ESSA postponed the special shareholder meeting to October 3 and will report the change in a Form 8‑K. » Más en de.investing.com
ESSA Pharma cuts payouts in amended merger agreement with XenoTherapeutics
ESSA Pharma has amended the terms of its takeover by XenoTherapeutics, reducing the cash payment at closing from about $1.91 to roughly $0.12 per share. In addition, shareholders will receive one non-transferable CVR per share with a potential additional payout of up to about $0.14 per CVR. The company cites potential liabilities, related costs and current cash balance forecasts as reasons; the extraordinary general meeting has been postponed to October 3. XOMA Royalty Corporation remains structuring adviser and financier of the transaction; InvestingPro considers ESSA undervalued at its current market capitalization. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2025, ESSA Pharma Inc ya ha pagado 1,44 € en dividendos. El último pago fue en agosto de 2025.
Datos financieros
En el último trimestre, ESSA Pharma Inc tuvo unos ingresos de 0 € y un beneficio neto de -3,4 M €
| (EUR) | junio de 2025 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -13,9 mil | - |
| Beneficio neto | -3,4 M | - |
| EBITDA | -4,22 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 8,67 M € |
Número de acciones | 47,31 M |
Máximo/mínimo de 52 semanas | 5,88 € - 0,16 € |
| Dividendos | No |
Beta | 1,53 |
Ratio P/E | -0,31 |
Ratio PEG | -0,04 |
Ratio P/B | 0,07 |
Ratio P/S | 0,00 |
Perfil de la empresa
ESSA Pharma Inc., una empresa farmacéutica en fase clínica, se dedica al desarrollo de terapias novedosas y patentadas para el tratamiento del cáncer de próstata. Desarrolla EPI-7386, un candidato de administración oral que se encuentra en un estudio clínico de Fase I para el tratamiento de pacientes con cáncer de próstata metastásico resistente a la castración. La compañía tiene acuerdos de colaboración con Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; y Astellas Pharma Inc. ESSA Pharma Inc. fue constituida en 2009 y tiene su sede en Vancouver, Canadá.
| Nombre | ESSA Pharma Inc |
| CEO | David Ross Parkinson |
| Sede | Vancouver,
bc Canadá |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 13/03/2015 |
| Empleados | 35 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | EPIX |